Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.9% – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA) fell 5.9% during trading on Monday . The stock traded as low as $4.85 and last traded at $4.8250. 1,991,801 shares changed hands during trading, a decline of 64% from the average session volume of 5,605,642 shares. The stock had previously closed at $5.13.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SANA shares. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Monday, December 1st. JMP Securities set a $8.00 price target on shares of Sana Biotechnology in a report on Thursday, October 30th. Wedbush lifted their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Citizens Jmp increased their price objective on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Price Performance

The business has a 50 day simple moving average of $4.39 and a 200 day simple moving average of $3.67. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -4.79 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. On average, equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Institutional Trading of Sana Biotechnology

Several hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. increased its position in shares of Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after purchasing an additional 1,371,775 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares in the last quarter. Marex Group plc purchased a new position in Sana Biotechnology in the second quarter valued at $10,423,000. JPMorgan Chase & Co. raised its stake in Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after buying an additional 1,375,029 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its holdings in Sana Biotechnology by 33.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.